Sleeve Gastrectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure in which approximately 80% of the stomach is permanently removed along the greater curvature, leaving a narrow tubular "sleeve" roughly the size and shape of a banana. It is now the most commonly performed bariatric operation worldwide, accounting for over 60% of all weight-loss surgeries globally.

The procedure is performed laparoscopically under general anaesthesia through 4–6 small incisions. A calibration bougie — typically 32 to 36 French in diameter — is passed orally into the stomach to guide the surgeon in sizing the sleeve precisely. A linear stapler is then fired along the bougie, resecting the fundus and greater curve while preserving the pylorus and the gastroesophageal junction. The excised portion of the stomach is removed entirely from the body.

Unlike gastric bypass, sleeve gastrectomy does not reroute the intestines, so nutrient absorption remains largely intact in the early post-operative period. However, the procedure produces profound hormonal changes beyond simple restriction: the fundus is the primary site of ghrelin production, and its removal results in a significant and sustained reduction in circulating ghrelin levels — the hunger-stimulating hormone. This hormonal effect contributes substantially to appetite suppression and metabolic improvements independent of the mechanical restriction alone.

LSG can also serve as the first stage of a two-stage bariatric approach in super-obese patients (BMI >60 kg/m²) or those with high anaesthetic risk, with conversion to Roux-en-Y gastric bypass (RYGB) or one-anastomosis gastric bypass (OAGB) performed later once initial weight loss reduces operative risk.

Sleeve gastrectomy is indicated primarily for severe obesity and its metabolic comorbidities. The conditions most commonly addressed include:

• Morbid obesity (Class III): BMI ≥40 kg/m² without comorbidities, or BMI ≥35 kg/m² with serious weight-related health conditions. LSG achieves durable weight loss that other methods have failed to sustain.
• Type 2 diabetes mellitus (T2DM): Metabolic improvement is well-documented. The SLEEVEPASS randomised controlled trial (Salminen et al., NEJM 2018) demonstrated 37% T2DM remission at 5 years with sleeve, compared to 45% with RYGB — RYGB showing superior metabolic outcomes but with more complications. For patients with moderate T2DM and acceptable GERD risk, LSG remains an appropriate choice.
• Obstructive sleep apnoea (OSA): Significant weight loss frequently leads to resolution or substantial improvement in OSA severity and reduced CPAP dependency.
• Hypertension and dyslipidaemia: Blood pressure and lipid profiles improve markedly in most patients within months of surgery, often enabling medication reduction.
• Non-alcoholic fatty liver disease (NAFLD) and NASH: Histological improvement in liver steatosis and fibrosis has been documented following LSG.
• Polycystic ovary syndrome (PCOS): Hormonal normalisation, restoration of ovulatory cycles, and improved fertility outcomes are reported in women of reproductive age.
• Gastro-oesophageal reflux disease (GERD): While pre-existing mild GERD is not an absolute contraindication, severe Barrett's oesophagus or medically refractory GERD typically favours RYGB over LSG due to the risk of new or worsening reflux post-sleeve.

Candidacy for laparoscopic sleeve gastrectomy is determined through a comprehensive multidisciplinary assessment involving a bariatric surgeon, dietitian, psychologist, and physician. Standard internationally accepted criteria include:

• BMI criteria: BMI ≥40 kg/m² (morbid obesity), or BMI 35–39.9 kg/m² with at least one serious obesity-related comorbidity such as T2DM, hypertension, OSA, or joint disease. In Asian populations and selected metabolic cases, lower BMI thresholds (≥32.5 kg/m²) may apply per local guidelines.
• Failed conservative management: Documented failure of supervised diet, exercise, and behavioural modification programmes for at least 6–12 months. Anti-obesity medications may have been trialled.
• Age: Typically 18–65 years. Adolescent surgery (16–17 years with severe comorbidities) is considered in specialist paediatric bariatric centres. Upper age limits are individualised based on functional status, not chronological age alone.
• Psychological stability: Absence of untreated active psychiatric conditions, substance misuse, or binge-eating disorder that would undermine post-operative adherence. Pre-operative psychological assessment is mandatory.
• Commitment to lifestyle change: Patients must demonstrate understanding of the lifelong dietary modifications, supplement adherence, and follow-up requirements.

Absolute contraindications include uncontrolled psychiatric illness, active substance dependence, severe coagulation disorders, pregnancy, and Barrett's oesophagus with high-grade dysplasia. Significant GERD with oesophagitis is a relative contraindication favouring RYGB. Pre-operative upper GI endoscopy, nutritional blood panel, cardiopulmonary assessment, and sleep study are standard components of the work-up.

Laparoscopic sleeve gastrectomy is performed under general anaesthesia with the patient in the reverse Trendelenburg position. Key technical steps include:

• Port placement: Four to six laparoscopic ports are placed in the upper abdomen. A 5 mm liver retractor port retracts the left lobe of the liver for optimal gastric exposure.
• Greater omentum mobilisation: The greater curve of the stomach is mobilised from the pylorus (approximately 4–6 cm from the pyloric valve distally) up to the angle of His, dividing short gastric vessels and gastrocolic ligament attachments.
• Bougie calibration: A 32–36 French orogastric bougie is passed under direct vision along the lesser curve. Bougie size influences residual sleeve volume — smaller bougie (32Fr) creates a tighter sleeve associated with greater restriction and higher leak risk; 36Fr is more commonly used to balance restriction with safety.
• Stapling: Multiple firings of a linear endoscopic stapler (typically 60 mm loads with green or gold cartridges for the thicker gastric tissue) are used to divide the stomach along the bougie, creating the sleeve. Staple line reinforcement — using absorbable polymer membrane, over-sewing, or fibrin sealant — is used variably across centres, with some evidence supporting reduced leak rates.
• Leak test: An intraoperative methylene blue or air insufflation test under saline is performed to verify staple line integrity before closure.
• Drain placement: A closed-suction drain is routinely placed near the staple line, particularly at the gastroesophageal junction — the anatomical site of highest leak risk.

Conversion to OAGB or RYGB may be planned secondarily if GERD worsens or weight regain occurs after adequate trial. Average operative time is 60–90 minutes in experienced centres.

Sleeve gastrectomy produces substantial, durable weight loss and metabolic improvements supported by robust clinical evidence:

• Weight loss: Average excess weight loss (%EWL) of 60–70% at 12 months, with total body weight reduction of 25–35%. Long-term studies show maintenance of 50–60% EWL at 5 years in adherent patients, though weight regain is documented in 20–30% at 10 years.
• Ghrelin suppression: Removal of the gastric fundus eliminates the primary source of ghrelin, the appetite-stimulating hormone. Circulating ghrelin levels fall by 60–80% post-operatively, contributing to reduced hunger and improved satiety independent of food restriction.
• T2DM remission: Partial or complete T2DM remission in 37–45% of patients at 5 years. Glycaemic improvement often precedes significant weight loss, confirming a weight-independent metabolic mechanism.
• Cardiovascular risk reduction: Significant reduction in hypertension, dyslipidaemia, and estimated 10-year cardiovascular event risk. Swedish Obese Subjects data demonstrate reduced all-cause and cardiovascular mortality after bariatric surgery.
• OSA improvement: Polysomnographic resolution or significant improvement in apnoea-hypopnoea index (AHI) in majority of patients, with many achieving CPAP discontinuation.
• Quality of life: Validated tools (BAROS, SF-36) show sustained improvements in physical function, mental health, and social participation at 1–5 years post-surgery.
• Preserved pyloric function: Unlike bypass procedures, the pylorus is retained, maintaining regulated gastric emptying and reducing risk of dumping syndrome.

As with all major surgical procedures, laparoscopic sleeve gastrectomy carries defined risks that patients should understand before consent:

• Staple line leak (0.5–1%): The most serious early complication. Risk is highest at the gastroesophageal junction (angle of His) where tissue is thicker and stapling more challenging. Presentation typically occurs on day 3–7 with fever, tachycardia, and left shoulder tip pain. Management depends on severity: contained leaks may be managed conservatively with drainage, parenteral nutrition, and antibiotics; large or uncontained leaks require endoscopic stent placement (self-expanding covered metal stent for 6–8 weeks) or rarely surgical re-intervention. Mortality from leak is approximately 0.1% in high-volume centres.
• Bleeding (1–2%): Can occur from the staple line or short gastric vessel stumps. Most are managed conservatively or with laparoscopic re-exploration.
• Gastro-oesophageal reflux disease (GERD): New-onset or worsened GERD occurs in 20–30% of patients due to reduced lower oesophageal sphincter pressure and altered gastric anatomy. Persistent medically refractory GERD may necessitate conversion to RYGB.
• Stricture or sleeve stenosis (0.1–0.5%): Narrowing of the sleeve, usually at the incisura angularis, presenting with dysphagia and vomiting. Managed with endoscopic balloon dilation.
• Nutritional deficiencies: Reduced intake and altered food tolerance lead to deficiencies in vitamin B12, iron, folate, vitamin D, and calcium. Life-long supplementation with a high-dose multivitamin is mandatory.
• Venous thromboembolism (VTE): Mitigated by early mobilisation, pneumatic compression, and low-molecular-weight heparin prophylaxis commenced pre-operatively.
• Weight regain: Gradual sleeve dilation and return of appetite in 20–30% of patients over 5–10 years. Revision surgery options include conversion to RYGB or OAGB.

Post-operative care following sleeve gastrectomy is structured and lifelong. Adherence to follow-up protocols is strongly correlated with long-term success:

• Hospital stay: Typically 1–3 days. Oral sips commence the day of surgery; a full liquid diet begins on day 1 if tolerating well.
• Dietary progression: Phase 1 (days 1–14): clear fluids and protein shakes. Phase 2 (weeks 2–4): pureed foods. Phase 3 (weeks 4–8): soft foods. Phase 4 (week 8 onwards): regular textured diet with emphasis on protein-first eating (minimum 60–80 g protein daily), small portions, slow eating, and avoidance of carbonated beverages which may expand the sleeve.
• Activity: Walking encouraged from day 1. Light exercise from week 2. Return to full physical activity at 4–6 weeks. Heavy lifting deferred for 6–8 weeks to allow port-site healing.
• Supplementation (lifelong): High-dose multivitamin with minerals, vitamin B12 (sublingual or injection preferred), iron with vitamin C, calcium citrate (not carbonate — requires acid for absorption), and vitamin D. Blood levels monitored at 3, 6, and 12 months, then annually.
• Clinic follow-up: At 2 weeks, 3 months, 6 months, 12 months, and annually thereafter with surgeon, dietitian, and where appropriate endocrinologist or physician for comorbidity management.
• Weight monitoring: Monthly self-weighing. Weight loss velocity of 1–2 kg/week expected in the first 3 months. Plateau phases are normal and do not indicate failure.
• Psychological support: Post-operative group support programmes and individual counselling are offered in comprehensive bariatric centres and are associated with better long-term outcomes.

The cost of laparoscopic sleeve gastrectomy varies considerably by country, hospital tier, and patient complexity. Key cost determinants include:

• Surgical expertise and hospital tier: Accredited centres of excellence (ASMBS, IFSO-certified) command higher fees but typically demonstrate lower complication rates, influencing total episode cost.
• Country of treatment: Approximate all-inclusive package costs range widely — India: USD 3,500–6,000; Turkey: USD 4,000–7,000; Thailand: USD 8,000–12,000; Mexico: USD 5,000–9,000; United Kingdom (private): GBP 8,000–14,000; United States: USD 15,000–25,000 (self-pay). NHS England provides LSG free at the point of care for eligible patients meeting NICE TA672 criteria.
• Pre-operative work-up: Investigations including endoscopy, sleep study, echocardiogram, and anaesthetic assessment add to total costs — typically USD 500–2,000 additional.
• Surgical consumables: Stapling devices, reinforcement materials, and laparoscopic instruments significantly affect hospital costs.
• Anaesthesia and operating theatre fees: Vary by duration and complexity; high-BMI patients may require specialist obesity anaesthesia teams.
• Post-operative supplements: Ongoing supplement costs of approximately USD 50–150/month should be factored into the long-term budget.
• Revision surgery: If conversion to RYGB or OAGB is later required, additional costs of USD 5,000–20,000 may apply depending on geography.

Medical tourism packages for bariatric surgery typically include surgery, 3–5 nights accommodation, airport transfers, and short-term follow-up, but patients must arrange longer-term follow-up with a local bariatric team on return home.

Several evidence-based alternatives exist, and the choice depends on BMI, comorbidities — particularly GERD and T2DM severity — surgical risk, and patient preference:

• Roux-en-Y Gastric Bypass (RYGB): Gold standard for patients with significant GERD, severe T2DM, or BMI >50. The SLEEVEPASS RCT (NEJM 2018) confirmed superior T2DM remission (45% vs 37%) with RYGB but higher rates of dumping syndrome, nutritional deficiency, and internal hernia. Considered when GERD is a primary concern or LSG has failed.
• One-Anastomosis Gastric Bypass (OAGB / Mini-Bypass): Single-loop bypass with good metabolic outcomes and shorter operative time than RYGB. Increasing evidence base; IFSO recognises as a standard procedure. Bile reflux risk requires careful patient selection.
• Adjustable Gastric Band (AGB): Largely fallen out of favour due to high long-term failure and revision rates (up to 40–50% at 10 years). Avoids stapling or bypass but provides inferior weight loss compared to LSG or RYGB.
• Intragastric Balloon (IGB): Non-surgical, endoscopically placed fluid-filled balloon for 6 months. Appropriate for BMI 27–40 as a bridge or for patients not yet meeting surgical criteria. Average EWL 25–35%; weight regain common after removal.
• Anti-obesity medications: GLP-1 receptor agonists (semaglutide, tirzepatide) demonstrate 15–20% body weight reduction in clinical trials — approaching surgical outcomes in some patients. May serve as an adjunct or alternative in those refusing or unsuitable for surgery.
• Intensive behavioural and dietary therapy: Supervised very-low-calorie diet (VLCD) with structured lifestyle programme. Effective short-term but limited long-term weight maintenance without surgical reinforcement.